Medical oncologists provide clinical insights on treatment paradigms for patients with castration-resistant prostate cancer, highlighting how next-generation sequencing informs treatment decisions.
Cabazitaxel/Abiraterone Yields PFS Improvement in mCRPC
CHAARTED2 trial showed an improved progression-free survival in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel, abiraterone acetate, and prednisone.
Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs
Judd W. Moul, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the treatment of a patients with evidence of prostate cancer despite multiple negative prognostic tests.
AI Use in Prostate Cancer: Potential Improvements in Treatments and Patient Care
Artificial intelligence use in prostate cancer encompasses 4 main areas including diagnostic imaging, prediction of outcomes, histopathology, and treatment planning.
Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer
Muhammad Rafay Khan Niazi, MD, and Alexander Bershadskiy, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the use of PARP inhibitors as maintenance therapy for certain patients with metastatic castration-resistant prostate cancer.
18F-PSMA-1007 PET/CT Improves Staging Vs MRI in Prostate Cancer
Findings support the use of 18F-PSMA-1007 PET/CT in the preoperative workflow of intermediate- and high-risk prostate cancer.
HIFU Yields Noninferior Outcomes Vs Prostatectomy in Local Prostate Cancer
Functional consequences appeared to be lower with HIFU compared with radical prostatectomy in a prospective trial.